Switch theme
Sign up to access all valuation multiples
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
1992
820
LTM Revenue $640M
LTM EBITDA $256M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hualan Biological Engineering has a last 12-month revenue (LTM) of $640M and a last 12-month EBITDA of $256M.
In the most recent fiscal year, Hualan Biological Engineering achieved revenue of $608M and an EBITDA of $224M.
Hualan Biological Engineering expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hualan Biological Engineering valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $640M | XXX | $608M | XXX | XXX | XXX |
| Gross Profit | $365M | XXX | $373M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $256M | XXX | $224M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 37% | XXX | XXX | XXX |
| EBIT | $200M | XXX | $176M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $164M | XXX | $151M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hualan Biological Engineering's stock price is CNY 16 (or $2).
Hualan Biological Engineering has current market cap of CNY 29.4B (or $4.1B), and EV of CNY 26.9B (or $3.7B).
See Hualan Biological Engineering trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $4.1B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hualan Biological Engineering has market cap of $4.1B and EV of $3.7B.
Hualan Biological Engineering's trades at 6.1x EV/Revenue multiple, and 16.7x EV/EBITDA.
Equity research analysts estimate Hualan Biological Engineering's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hualan Biological Engineering has a P/E ratio of 24.9x.
See valuation multiples for Hualan Biological Engineering and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.6x | XXX | 16.7x | XXX | XXX | XXX |
| EV/EBIT | 18.6x | XXX | 21.2x | XXX | XXX | XXX |
| EV/Gross Profit | 10.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.9x | XXX | 27.1x | XXX | XXX | XXX |
| EV/FCF | 23.0x | XXX | 33.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHualan Biological Engineering's last 12 month revenue growth is 13%
Hualan Biological Engineering's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Hualan Biological Engineering's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hualan Biological Engineering's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hualan Biological Engineering and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -11% | XXX | XXX | XXX |
| Rule of 40 | 57% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hualan Biological Engineering acquired XXX companies to date.
Last acquisition by Hualan Biological Engineering was XXXXXXXX, XXXXX XXXXX XXXXXX . Hualan Biological Engineering acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hualan Biological Engineering founded? | Hualan Biological Engineering was founded in 1992. |
| Where is Hualan Biological Engineering headquartered? | Hualan Biological Engineering is headquartered in China. |
| How many employees does Hualan Biological Engineering have? | As of today, Hualan Biological Engineering has 820 employees. |
| Is Hualan Biological Engineering publicy listed? | Yes, Hualan Biological Engineering is a public company listed on SHE. |
| What is the stock symbol of Hualan Biological Engineering? | Hualan Biological Engineering trades under 002007 ticker. |
| When did Hualan Biological Engineering go public? | Hualan Biological Engineering went public in 2004. |
| Who are competitors of Hualan Biological Engineering? | Similar companies to Hualan Biological Engineering include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hualan Biological Engineering? | Hualan Biological Engineering's current market cap is $4.1B |
| What is the current revenue of Hualan Biological Engineering? | Hualan Biological Engineering's last 12 months revenue is $640M. |
| What is the current revenue growth of Hualan Biological Engineering? | Hualan Biological Engineering revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Hualan Biological Engineering? | Current revenue multiple of Hualan Biological Engineering is 5.8x. |
| Is Hualan Biological Engineering profitable? | Yes, Hualan Biological Engineering is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hualan Biological Engineering? | Hualan Biological Engineering's last 12 months EBITDA is $256M. |
| What is Hualan Biological Engineering's EBITDA margin? | Hualan Biological Engineering's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Hualan Biological Engineering? | Current EBITDA multiple of Hualan Biological Engineering is 14.6x. |
| What is the current FCF of Hualan Biological Engineering? | Hualan Biological Engineering's last 12 months FCF is $162M. |
| What is Hualan Biological Engineering's FCF margin? | Hualan Biological Engineering's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of Hualan Biological Engineering? | Current FCF multiple of Hualan Biological Engineering is 23.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
